South & Central America Sarcopenia Treatment Market
The South & Central America sarcopenia treatment market was valued at US$ 189.59 million in 2022 and is expected to reach US$ 268.50 million by 2030; it is estimated to register a CAGR of 4.4% from 2022 to 2030.
A few major players operating in the sarcopenia treatment market are increasingly focusing on drug development to treat sarcopenia. Novel sarcopenia treatments are currently being developed and tested in clinical trials. A few of these products are mentioned below:
Company Name | Interventions | Conditions | Clinical Trial Stage |
Abbott Nutrition | Medical Food with AN777 Oral Nutritional Formula | Malnutrition Sarcopenia | PHASE3 |
Nutricia Research | Dietary Supplement: Bolus ONS A Dietary Supplement: Bolus ONS B Dietary Supplement: Bolus ONS C Dietary Supplement: Bolus ONS D | Sarcopenia | PHASE1 |
Novartis Pharmaceuticals | Drug: Bimagrumab | Sarcopenia | PHASE2 |
McMaster University | Behavioural: Step Reduction | Sarcopenia | PHASE1 |
Metabolic Technologies Inc. | Dietary Supplement: Placebo Drug: HMB Plus Vitamin D Behavioural: Non-Exercise Behavioural: Exercise | Sarcopenia | PHASE1 |
Merck Sharp & Dohme LLC | Drug: Comparator MK-077 Drug: Comparator Placebo | Sarcopenia | PHASE2 |
Immunotec Inc. | Dietary Supplement: Immunocal Dietary Supplement: Casein | Aging and Sarcopenia | PHASE2 |
Lijun Yang | Combination Product: 3-Month Intensive Intervention | Sarcopenia | PHASE4 |
Regeneron Pharmaceuticals | Drug: REGN1033 (SAR391786) Drug: Placebo | Sarcopenia | PHASE2 |
Source: Company Websites and The Insight Partners Analysis
Therefore, the extending pipeline of drugs that are in different stages of clinical development presents significant opportunities for the sarcopenia treatment market growth.
The sarcopenia treatment market in South & Central America is segmented into Brazil, Argentina, and the Rest of South & Central America. A rise in the geriatric population and the surging incidence of vitamin Deficiency fuels the sarcopenia treatment market in South & Central America.
The introduction of new regulations by the National Sanitary Surveillance Agency (ANVISA) for dietary supplements in 2018 made the entry of new brands easier in Brazil. Moreover, it helped existing brands to flourish and innovate in the country. According to a study published in the National Library of Medicine, the elderly population is rapidly growing in Brazil, resulting in an increased prevalence of chronic conditions associated with old age. The overall prevalence of sarcopenia in the elderly population in Brazil was ~20.0% in 2020. According to an article published by National Institute of Health, in 2022, the prevalence of probable sarcopenia is 42.0% in older Brazilian women.
Strategic insights for the South & Central America Sarcopenia Treatment provides data-driven analysis of the industry landscape, including current trends, key players, and regional nuances. These insights offer actionable recommendations, enabling readers to differentiate themselves from competitors by identifying untapped segments or developing unique value propositions. Leveraging data analytics, these insights help industry players anticipate the market shifts, whether investors, manufacturers, or other stakeholders. A future-oriented perspective is essential, helping stakeholders anticipate market shifts and position themselves for long-term success in this dynamic region. Ultimately, effective strategic insights empower readers to make informed decisions that drive profitability and achieve their business objectives within the market.
| Report Attribute | Details |
|---|---|
| Market size in 2022 | US$ 189.59 Million |
| Market Size by 2030 | US$ 268.50 Million |
| Global CAGR (2022 - 2030) | 4.4% |
| Historical Data | 2020-2021 |
| Forecast period | 2023-2030 |
| Segments Covered |
By Treatment Type
|
| Regions and Countries Covered | South and Central America
|
| Market leaders and key company profiles |
The geographic scope of the South & Central America Sarcopenia Treatment refers to the specific areas in which a business operates and competes. Understanding local distinctions, such as diverse consumer preferences (e.g., demand for specific plug types or battery backup durations), varying economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved areas or adapting their offerings to meet local demands. A clear market focus allows for more effective resource allocation, targeted marketing campaigns, and better positioning against local competitors, ultimately driving growth in those targeted areas.
The South & Central America is categorized into treatment type, distribution channel, and country.
Based on treatment type, the South & Central America sarcopenia treatment market is segmented into vitamin D and calcium supplement, protein supplement, vitamin B12 supplement, and others. The vitamin D and calcium supplement segment held the largest South & Central America sarcopenia treatment market share in 2022.
In terms of distribution channel, the South & Central America sarcopenia treatment market is segmented into pharmacies, retail channels, online channels, and others. The pharmacies segment held the largest South & Central America sarcopenia treatment market share in 2022.
By country, the South & Central America sarcopenia treatment market is segmented into Brazil, Argentina, and the Rest of South & Central America. Brazil dominated the South & Central America sarcopenia treatment market share in 2022.
Abbott Laboratories, Bayer AG, Nestle Health Science SA, Novartis AG, Pfizer Inc, Sanofi SA, Amway Corp, and GSK Plc are some of the leading companies operating in the South & Central America sarcopenia treatment market.
1. Abbott Laboratories
2. Bayer AG
3. Nestle Health Science SA
4. Novartis AG
5. Pfizer Inc
6. Sanofi SA
7. Amway Corp
8. GSK Plc
The South & Central America Sarcopenia Treatment Market is valued at US$ 189.59 Million in 2022, it is projected to reach US$ 268.50 Million by 2030.
As per our report South & Central America Sarcopenia Treatment Market, the market size is valued at US$ 189.59 Million in 2022, projecting it to reach US$ 268.50 Million by 2030. This translates to a CAGR of approximately 4.4% during the forecast period.
The South & Central America Sarcopenia Treatment Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the South & Central America Sarcopenia Treatment Market report:
The South & Central America Sarcopenia Treatment Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The South & Central America Sarcopenia Treatment Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the South & Central America Sarcopenia Treatment Market value chain can benefit from the information contained in a comprehensive market report.
E 1803, Panchshil Towers, Vagholi, Haveli, Pune- 412207, Maharashtra, India
US:+16467917070
sales@businessmarketinsights.com
Get Free Sample For South & Central America Sarcopenia Treatment Market
